BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ImmuCell (ICCC) Appoints David S. Cunningham to Board of Directors


9/7/2011 9:27:29 AM

PORTLAND, ME--(Marketwire - September 07, 2011) - ImmuCell Corporation (NASDAQ: ICCC) today announced that Mr. David S. Cunningham was appointed to serve on the Company's Board of Directors.

Mr. Cunningham is President and CEO of Teva Animal Health located in St. Joseph, Missouri. He was previously Executive Vice President of Sales and Marketing for Agri Laboratories Ltd. and before that Vice President of Sales and Marketing, Cattle Division, for Boehringer Ingelheim Vetmedica, Inc. Previously, he worked for Hoechst-Roussel Vet and Lextron Animal Health. Mr. Cunningham is a graduate of Iowa State University.

"We are fortunate to add David's extensive experience in the animal health industry to our board," commented Michael F. Brigham, President and CEO. "We can benefit from his insight and his animal health deal-making and product launch and marketing experience."

"I have followed ImmuCell for some time now and am impressed with the management and leadership team, as well as the strong performance of its commercial business with the flagship product, First Defense®," commented Mr. Cunningham. "I am also excited for the future of the company with the novel technology it has in development. I look forward to providing input to management at this important time in the Company's development."

About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).


Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES